Anzeige
Mehr »
Login
Montag, 21.10.2024 Börsentäglich über 12.000 News von 675 internationalen Medien
Der Warren Buffett des Bergbaus schlägt wieder zu: NexGold Mining auf dem Weg zur Milliardenbewertung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0B6G4 | ISIN: SE0001161654 | Ticker-Symbol: NQA
Frankfurt
18.10.24
08:24 Uhr
11,050 Euro
-0,040
-0,36 %
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
NOTE AB Chart 1 Jahr
5-Tage-Chart
NOTE AB 5-Tage-Chart
GlobeNewswire (Europe)
59 Leser
Artikel bewerten:
(0)

NOTE AB: NOTE's Third-quarter Interim Report 2024

Financial performance in July-September
• Sales amounted to SEK 809 (1,034) million. Adjusted for acquisitions and currency effects, organic growth was -20%.
• Operating profit was SEK 64 (94) million. Adjusted operating profit was SEK 67 (94) million, adjusted for revaluations of operating assets and liabilities in foreign currencies, as well as the year's provision to the restructuring reserve.
• The operating margin amounted to 8.0% (9.1%). The adjusted operating margin was 8.3% (9.0%), adjusted for currency revaluations and the year's provision to the restructuring reserve.
• Profit after financial items was SEK 55 (80) million.
• Profit after tax amounted to SEK 43 (65) million, corresponding to SEK 1.52 (2.24) per share.
• Adjusted for acquisition-related payments made in the quarter, operating cash flow after investments was SEK 157 (34) million. Total cash flow after investments, including acquisitions, amounted to SEK 120 (-57) million, or SEK 4.21 (-1.97) per share.

Financial performance in January-September
• Sales amounted to SEK 2,876 (3,163) million. Adjusted for acquisitions and currency effects, organic growth was -11%.
• Operating profit was SEK 254 (312) million. Adjusted operating profit was SEK 256 (308) million, adjusted for revaluations of operating assets and liabilities in foreign currencies, as well as the year's provision to the restructuring reserve.
• The operating margin amounted to 8.8% (9.9%). The adjusted operating margin was 8.9% (9.7%), adjusted for currency revaluations and the year's provision to the restructuring reserve.
• Profit after financial items was SEK 219 (280) million.
• Profit after tax amounted to SEK 175 (229) million, corresponding to SEK 6.06 (7.89) per share.
• Adjusted for acquisition-related payments made in the period, operating cash flow after investments was SEK 398 (135) million. Total cash flow after investments, including acquisitions, amounted to SEK 341 (-10) million, or SEK 11.97 (-0.35) per share.

CEO's comment - We think achieving underlying profitability of 8.3% in the quarter is a sign of strength. We're proud that we've succeeded in maintaining high profitability by continuously adapting our business, even when we're not getting the volumes we planned for.

"Third-quarter sales did not progress as we anticipated and were significantly below our expectations. Sales in Q3 were SEK 809 million, equivalent to negative organic growth of 20%. We're far from satisfied with this, and we know we have a stronger customer portfolio than it suggests.

We think achieving underlying profitability of 8.3% in the quarter is a sign of strength. Growth generates profitability, and when the growth our customers have been signalling and placed orders for is deferred, this obviously has an impact. Even if our ambitions for operating margin are higher, we're proud that by continuously adapting our business, we succeeding in keeping our margin over 8% despite us not getting the volumes we planned for. We're working continuously on rationalising, and still see potential here.

It's gratifying that our operating cash flow was SEK 157 million in the third quarter, which is also in line with plan. The corresponding number for the first three quarters of the year was SEK 398 million. We expect our strong cash flows to continue going forward. NOTE's financial situation remains really positive with an equity to assets ratio of 49% and net debt of SEK 203 million (adjusted for leased properties under IFRS 16).

We see a brisk finish to the year and reiterating our guidance of sales for the fourth quarter of SEK 975-1,025 million and a minimum operating margin of 9.5%." says Johannes Lind-Widestam, CEO and president.

NOTEs Interim Report for Q3 2024 is now available in PDF format on the corporate web site, www.note-ems.com, and attached to this message. Today at 10.00 CET, NOTE organizes a presentation for analysts, media and investors, where CEO and President Johannes Lind-Widestam presents the report. The Year-end Report for January-December will be published on January 27, 2025.

For more information, please contact:
Johannes Lind-Widestam, CEO and President, tel. +46 (0)70 541 7222
Frida Frykstrand, CFO, tel. +46 (0)70 462 0939

About NOTE
NOTE produces PCBAs, subassemblies and box build products. NOTE is a competitive EMS provider and stable business partner to customers with high standards. NOTE's products are embedded in complex systems for electronic control, surveillance and security, for example.

NOTE's business model builds on delivering high end manufacture, custom logistics solutions and consulting for the best possible total cost through long-term customer relationships and partnerships. Its customer offering covers complete product lifecycles, from design to after-sales. Primarily, its customer base consists of large corporations operating on the global market, and enterprises whose main sales are in northern Europe.

NOTE has a presence in Sweden, Finland, the UK, Estonia, Bulgaria and China. Sales over the last 12 months were SEK 3,956 million, and the group has approximately 1,500 employees. NOTE is listed on Nasdaq Stockholm. For more information, please go to www.note-ems.com.

This information is information that NOTE AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-10-14 08:00 CEST.

© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.